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ABSTRACT 
Facial malformations represent one of the most frequent abnormality in humans. The adverse 
outcome pathway involved in facial defects seems to be related to retinoic acid (RA) pathway 
imbalance. Environmental agents inducing cranio-facial malformations in experimental models 
include pesticides (especially azole fungicides). By using the in vitro alternative method 
postimplantation rat whole embryo culture (WEC), we evaluated the intrinsic embryotoxic activity 
of some azole antifungals (cyproconazole, CYPRO; triadimefon, FON; flusilazole, FLUSI and 
prochloraz, PCZ), in comparison to RA. All the tested molecules induced in a dose-related manner 
specific defects of the cranio-facial structures (fused branchial arches), similar to those induced by 
RA. Collected data were modelled by using PROAST 65.5 software in order to characterize the 
relative potency factors (RPFs) versus RA. In comparison to RA, all the evaluated azoles were less 
potent, showing among them a similar potency. Our data suggest a possible azole-related RA 
signaling perturbation to be further investigated. Moreover, the present results indicate the approach 
used in this work as an interesting tool applicable to the hazard evaluation of novel compounds or 
assessment of combined exposure to azoles or other dismorphogens. 
Keywords: 
 Azole, retinoic acid, malformation, potency, PROAST.
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1. INTRODUCTION 
 
Among congenital anomalies in humans, oral clefts in any form (cleft lip and/or palate alone or 
associated with other head skeletal defects) occur in about 1:700 live births, both as isolated 
anomalies and in syndromic conditions (Mossey et al., 2009). Evidence suggests that oral clefts are 
multifactorial in origin, involving both genetic and environmental risk factors (Mossey et al, 2009).  
The elucidation of the different pathways contributing to cranio-facial morphogenesis and of their 
disturbance by different chemicals is fundamental in order to evaluate the contribution of multiple 
exposures to the incidence of cranio-facial defects. 
Retinoic acid (RA), the active metabolite of vitamin A, is the main regulator of embryo 
development (Metzler and Sandell, 2016) controlling also the normal cranio-facial morphogenesis. 
Both deficiency and excess of embryonic RA are related to malformations at multiple districts, 
including cranio-facial defects in humans and animals (Warkany and Schraffenberger, 1944; 
Lammer et al., 1985; Hathcock et al., 1990; Morriss-Kay, 1992; Browne et al., 2014; Piersma et al., 
2017). In the presence of excess of RA, postimplantation rodent whole embryo cultures (WEC) 
show specific defects, including branchial arch (the embryonic facial primordial) abnormalities 
(Klug et al., 1989; Menegola et al., 2004). 
Antifungal azoles are a group of fungistatic agents used both in clinical and veterinary practice as 
well as in agriculture. A number of adverse effects via non genotoxic mechanisms has been 
observed in laboratory animals, such as effects on liver, on reproduction, and developmental 
defects. In vivo experimental studies, case reports and a recent birth defect prevention study relate 
in utero exposure to some azole fungicides to cranio-facial defects (Tachibana et al., 1987; Lee et 
al., 1992; Pursley et al., 1996; Aleck and Bartley, 1997; Sanchez and Moya, 1998; Lopez-Rangel 
and Van Allen, 2005; Menegola et al., 2005; Di Renzo et al., 2011a; Howley et al., 2016). The 
teratogenic effect of certain azole fungicides in WEC has been documented in the past, describing 
abnormalities at the branchial arch apparatus level (Tiboni, 1993; Menegola et al., 2000, 2001, 
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2003, 2004, 2005; Di Renzo et al., 2011b). The hypothetical mode of action for cranio-facial 
defects of the teratogenic antifungal azoles is the inhibition of embryonic CYP26, that metabolizes 
RA, with consequent increase of endogenous RA content (Tiboni et al., 2009; Giavini and 
Menegola, 2010; Robinson et al., 2012; Piersma et al., 2017). An azole-related RA pathway 
imbalance has been recently described by using a transcriptomic approach (Dimopoulou et al., 
2017a, 2017b). 
Increasingly, the focus of risk assessment is on combined exposures, and for those molecules 
sharing the same mode of action, dose additivity with the use of relative potency factor (RPF) 
approach has been suggested (Hardy et al., 2017). RPF method entails scaling the toxicity of each 
individual component in the combined exposures to the toxicity of an index compound.  
The aim of the present work is to define RA-relative potency of four antifungal azoles by fitting 
WEC experimental data by using PROAST software analysis (www.proast.nl) (modelling 
procedure according to Slob, 2002; Moretto et al., 2015). The chemicals known to induce cranio-
facial defects selected in the present work are RA and azole antifungals (cyproconazole, CYPRO; 
flusilazole, FLUSI; triadimefon, FON; prochloraz, PCZ).  
Three of these azoles (CYPRO, FON, FLUSI) are known to induce cranio-facial defects after in 
utero exposure (FAO/WHO 2005; 2008; 2011; Menegola et al., 2005) and branchial defects in vitro 
(Menegola et al., 2000; 2001; Di Renzo et al., 2011b). Prochloraz (PCZ), an azole with broad 
spectrum fungistatic activity, induced maternotoxicity and embryotoxicity but not malformations 
after exposure in utero during the entire gestation (FAO/WHO, 2002) . No data are available on 
PCZ embryotoxicity when exposure duration was limited to the organogenetic period or after 
embryo exposure in vitro. PCZ has been selected in order to evaluate its intrinsic activity on embryo 
development in absence of maternal compartment. RA has been chosen in the present work as index 
compound in light of the fact that azoles are suspected to interfere with RA catabolism, thereby 
causing an increase in RA levels in specific embryo segments. 
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2. MATERIALS AND METHODS 
 
2.1. Materials and compound preparation.  
All the tested compounds were purchased by Sigma, Italy. Azoles were dissolved in ethanol 
(Sigma), RA was dissolved in DMSO (Sigma). The medium used for the extraction of embryos 
from the uteri was sterilized Tyrode solution (Sigma); the medium used for the postimplantation 
whole embryo culture was undiluted heat inactivated rat serum added with antibiotics (penicillin 
100 IU/mL culture medium and streptomycin 100µg/mL culture medium, Sigma).  
 
2.2. Selection of compound concentrations.  
The concentrations of test molecules were selected from previous published experiments on rat 
WEC in order to gradually achieve the maximum degree of severity for branchial malformations: 
RA 0.025-1µM (Menegola et al., 2004), CYPRO 7.8-250µM (Di Renzo et al. 2011), FON 6.25-
125µM (Menegola et al. 2000, Di Renzo et al. 2011b), FLUSI 1.56-125µM (Menegola et al. 2001).  
PCZ concentrations were selected on the basis of an unpublished range-finding test (6.25-50µM). 
For each dose-response experiment a group exposed to the relative solvent (dose 0) was performed. 
 
2.3. Embryo culture.  
Virgin female CD:Crl rats (Charles River, Calco, Italy), housed in a thermostatically maintained 
room (T = 22 ± 2 °C; relative humidity 55 ± 5%) with a 12 h light cycle (light from 6.00 a.m. to 
6.00 p.m.), free access to food (Italiana Mangimi, Settimo Milanese, Italy) and tap water  , were 
caged overnight with males of proven fertility. All animal use protocols were approved by the 
Ministry of Health - Department for Veterinary Public Health, Nutrition and Food Safety 
committee. Animals were treated humanely and with regard for alleviation of suffering. 
Embryos were explanted from untreated pregnant rats at E9.5 (early neurula stage, 1–3 somites; day 
of positive vaginal smear = 0) and cultured according to the New’s method (1978) in 20 ml glass 
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bottles (5 embryos/bottle), containing 5 mL culture medium. At least a triplicate was performed for 
each group. 
The bottles, inserted in a thermostatic (37.8°C) roller (30 rpm) apparatus, were periodically gas 
equilibrated according to Giavini et al. (1992). After 48 h of culture, embryos were morphologically 
examined under a dissecting microscope in order to evaluate any branchial or extra-branchial 
abnormality.  
 
 
2.4. PROAST modelling.  
The statistical analysis is done by dose-response modeling using PROAST. PROAST is a software 
package that has been developed by the Dutch National Institute for Public Health and the 
Environment (RIVM) (www.proast.nl) for the statistical analysis of dose-response data (65.5 
version). Results on branchial arch abnormalities have been modelled according to the dose-
response analysis for quantal data.  
The first step was the analysis of individual datasets in order to obtain dose-response curves for 
single compounds setting the benchmark dose (BMD) at 50% response (BMR). Exponential model 
family equations have been selected in order to describe the dose-response curves and obtain RPFs 
versus the index compound (in our case, RA). Log-likelihood ratio test has been applied in order to 
assess the equal steepness assumption.  
 
 
3. RESULTS  
 
3.1. Effects of exposure to RA, CYPRO, FON, FLUSI, PCZ on rat embryo development.  
After 48 h in culture, normal embryos are dorsally convex and reached the phylotypic stage: 
tripartite encephalon (forebrain, midbrain, hindbrain) with enlarged ventricles, open posterior 
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neuropore, three well separated branchial arches (the embryonic precursors of facial structures) (Fig 
1 A).  
Dose-related teratogenic effects were detected in embryos exposed to the different chemicals. A 
syndromic picture was observed after RA exposure at concentration level≥ 0.125µM. The affected 
districts were encephalon (swollen and short romboencephalon, microcephalia), branchial apparatus 
(fused branchial arches with different severity degrees, as listed in Tab. 1), somites (fused) and tail 
(hook-shaped tail) at any effective concentration. By contrast, the exposure to FON at 
concentrations ≥12.5µM and FLUSI at concentrations ≥3.13µM affected only the branchial 
apparatus (fused branchial arches). Branchial arches resulted malformed after exposure to CYPRO 
at concentrations ≥ 7.8µM and PCZ at concentrations ≥ 6.25µM, while other districts were affected 
only at the highest concentrations (CYPRO 250 µM, tail malformations; PCZ 25-50 µM 
abnormalities at the encephalon, somites and tail). Branchial defects are listed in Tab. 1 and 
consisted in different degrees of fusion among branchial arches: II-III unseparated branchial arches, 
I-II-III branchial arches ventrally fused (dorsal radicles visible), I-II-III branchial arches totally 
fused (dorsal radicles undistinguishable) or I-II-III branchial arches forming an unique mass (Fig. 1 
B-E). 
 
3.2. PROAST analysis 
PROAST analysis was applied to branchial outcomes only, because this apparatus was the common 
target for all the tested substances.  
Data were modelled to obtain the single dose-response curves (Figs 2-6); from these curves, the 
benchmark dose (BMD) for benchmark response (BMR) at 50% have been calculated (Tab. 2).  
Data from all compounds were analyzed together by using the exponential model to calculate the 
RPFs (Tab. 3; Fig. 7). Log-likelihood ratio test showed that equal steepness assumption is not 
rejected (p=0. 498 with log-likelihood of separate fits=132.31, log-likelihood of the overall 
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fit=129.13, degrees of freedom=7) (Tab. 2). All the tested azoles were similar among each other 
and less potent than RA (Tab.3).  
 
4. DISCUSSION 
 
The WEC is a validated toxicological in vitro method (Corvi et al., 2006; ECVAM, 2006; Flick and 
Klug, 2006) that can be useful also for mechanistic and modelling approaches (Robinson et al., 
2012; Menegola et al., 2013; Zhang et al., 2016; Dimopoulou et al., 2017a, 2017b). In vitro 
methods are in general encouraged in toxicity assessment to apply the RPF approach (EFSA, 2008). 
In agreement to previous WEC studies (Tiboni, 1993; Menegola et al., 2000, 2001, 2003, 2004, 
2005; Di Renzo et al., 2011b), we observed a clear dose-response in rat embryos exposed in vitro to 
RA and to the tested azoles, including the newly studied PCZ. The specific target for all tested 
azoles was the branchial apparatus, affected also by RA exposure. The branchial arches are typical 
embryonic structures involved in cranio-facial morphogenesis. Local perturbation of endogenous 
RA levels, mediated by the azole-dependent inhibition of RA catabolism (inhibition of CYP26 
enzyme), is the  proposed mode of action for azoles (Tiboni et al., 2009; Giavini and Menegola, 
2010; Robinson et al., 2012; Piersma et al., 2017). As previously suggested, the inhibition of 
embryonic CYP26 isoenzymes could indirectly increase the local endogenous concentration of RA 
at the branchial apparatus level (Menegola et al., 2004). Using a transcriptomic approach, 
Dimopoulou et al. (2017a, 2017b) indicate a correlation between CYP26-dependent RA-pathway 
perturbation and azole embryotoxicity in rat embryos cultured in vitro.  
In the present work, experimental data have been modelled by using the PROAST software, 
considered a useful tool for an in-depth analysis of concentration-response data from in vitro studies 
(Piersma et al., 2008). First, we tested all dose-response curves for parallelism.  
RPFs versus RA chosen as index compound (IC) have been then calculated.  
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While RA was definitively the most potent, the potencies of the tested azoles are very similar. This 
result is of particular interest because suggests that the tested azoles have similar potency in 
inhibiting CYP26. As previously hypothesized, the specific inhibition of CYP26 could be the 
molecular initiating event, producing specific effects mainly at the branchial apparatus level 
because in rodents, at the evaluated stages, CYP26 isoforms are predominantly expressed in cranial 
region (Lee et al., 2017). As a consequence, a local increase of RA in that target region after azole 
exposure might be postulated. This interesting hypothesis needs to be more thoroughly investigated 
in ad hoc in vitro and in silico investigations. Finally, it is worth to keep in mind that RPFs obtained 
in vitro reflect only the potency of compounds at the target (internal dose), since they do not take 
into account differences in toxicokinetics. This could also justify the fact that PCZ was able to 
induce malformations in the present work but not after in utero exposure, where only 
maternotoxicity and embryolethality were reported (FAO/WHO, 2002).  Therefore, comparison 
with the external dose can be performed only if toxicokinetic information is available (Tan et al., 
2018). These may also include comparison of animal vs human in vitro metabolic information (Punt 
et al., 2017).  Hence, the selected in vitro method (WEC) could be an alternative method applicable 
to hazard evaluation of novel chemicals, as an initial screening not influenced by the species-
specific maternal toxicity. As previously suggested by EFSA scientific committee (Hardy et al., 
2017), simple but predictive alternative methods should be applicable to derive relative RPFs, 
essential also to evaluate the exposure to mixtures. On these bases, the WEC can be used to test 
both single azoles and mixtures and identify their effects on cranio-facial morphogenesis.  
 
CONFLICTS OF INTEREST: there are no conflicts of interest to declare. 
ANIMAL USE: All animal use protocols were in accordance to EU Directive 2010/63, approved by 
the Ministry of Health - Department for Veterinary Public Health, Nutrition and Food Safety 
committee (authorization number 14/2015).  
 10 
FUNDS: our research project received funding from the European Union Horizon 2020 Framework 
Program under Grant Agreement 633172 (European Test and Risk Assessment Strategies for 
Mixtures, EuroMix). This publication reflects only the authors’ views, and the European 
community is not liable for any use made of the information contained therein. 
 
REFERENCES 
Aleck, K.A., Bartley, D.L., 1997. Multiple malformation syndrome following fluconazole use in 
pregnancy: Report of an additional patient. Am. J. Med. Genet. 72, 253–256. 
https://doi.org/10.1002/(SICI)1096-8628(19971031)72:3<253::AID-AJMG1>3.0.CO;2-S 
Belz, R.G., Hurle, K., Duke, S.O., 2005. Dose-Response—A Challenge for Allelopathy? 
Nonlinearity Biol. Toxicol. Med. 3, nonlin.003.02.0. 
https://doi.org/10.2201/nonlin.003.02.002 
Browne, H., Mason, G., Tang, T., 2014. Retinoids and pregnancy: an update. Obstet. Gynaecol. 16, 
7–11. https://doi.org/10.1111/tog.12075 
Corvi, R. et al., 2006. Meeting report: Validation of toxicogenomics-based test systems: ECVAM-
ICCVAM/NICEATM considerations for regulatory use. Environ. Health Perspect. 114, 
420–429. 
 
Di Renzo, F. et al, 2011a. Stage-dependent abnormalities induced by the fungicide triadimefon in 
the mouse☆. Reprod. Toxicol. 31, 194–199. https://doi.org/10.1016/j.reprotox.2010.10.011 
Di Renzo, F. et al., 2011b. Early genetic control of craniofacial development is affected by the in 
vitro exposure of rat embryos to the fungicide triadimefon. Birth Defects Res. B. Dev. 
Reprod. Toxicol. 92, 77–81. https://doi.org/10.1002/bdrb.20284 
Dimopoulou, M. et al., I.M.C.M., Piersma, A.H., 2017a. A transcriptomic approach for evaluating 
the relative potency and mechanism of action of azoles in the rat Whole Embryo Culture. 
Toxicology 392, 96–105. https://doi.org/10.1016/j.tox.2017.09.014 
 11 
Dimopoulou, M. et al., 2017b. Embryotoxic and pharmacologic potency ranking of six azoles in the 
rat whole embryo culture by morphological and transcriptomic analysis. Toxicol. Appl. 
Pharmacol. 322, 15–26. https://doi.org/10.1016/j.taap.2017.03.001 
ECVAM, 2006. ECVAM DB-ALM: invittox protocol. Embryotoxicity testing in postimplantation 
embryo culture- Method of Piersma INVITTOX n° 123. 
EFSA, 2008. Opinion of the Scientific Panel on Plant Protection products and their Residues to 
evaluate the suitability of existing methodologies and, if appropriate, the identification of 
new approaches to assess cumulative and synergistic risks from pesticides to h: Opinion of 
the Scientific Panel on Plant Protection products and their Residues to evaluate the 
suitability of existing methodologies and, if appropri. EFSA J. 6, 705. 
https://doi.org/10.2903/j.efsa.2008.705 
FAO/WHO JMPR, 2002. Report of the 2001 JMPR FA/WHO Meeting of Experts- Prochloraz, 144-
149. 
http://www.fao.org/fileadmin/templates/agphome/documents/Pests_Pesticides/JMPR/Reports_1991
-2006/REPORT2001.pdf 
FAO/WHO JMPR, 2005. Pesticide Residues in Food - 2004 - Toxicological evaluations - 
Triadimefon, 325-386.  http://apps.who.int/pesticide-residues-jmpr-
database/pesticide?name=TRIADIMEFON 
FAO/WHO JMPR, 2008. Pesticide Residues in Food – 2007- Toxicological Evaluations – 
Flusilazole, 317-347. http://apps.who.int/pesticide-residues-jmpr-
database/pesticide?name=FLUSILAZOLE 
FAO/WHO JMPR, 2011. Pesticide Residues in Food – 2010- Toxicological Evaluations – 
Cyproconazole, 117-202. http://apps.who.int/pesticide-residues-jmpr-
database/pesticide?name=CYPROCONAZOLE 
 
 
 12 
Flick, B., Klug, S., 2006. Whole Embryo Culture: An Important Tool in Developmental Toxicology 
Today. Curr. Pharm. Des. 12, 1467–1488. https://doi.org/10.2174/138161206776389822 
Giavini, E. et al., 1992. Effects of ethanol and acetaldehyde on rat embryos developing in vitro. 
Vitro Cell. Dev. Biol. - Anim. 28, 205–210. https://doi.org/10.1007/BF02631093 
Giavini, E., Menegola, E., 2010. Are azole fungicides a teratogenic risk for human conceptus? 
Toxicol. Lett. 198, 106–111. https://doi.org/10.1016/j.toxlet.2010.07.005 
Hardy, A. et al., 2017. Update: use of the benchmark dose approach in risk assessment. EFSA J. 15. 
https://doi.org/10.2903/j.efsa.2017.4658 
Hathcock, J.N.et al., 1990. Evaluation of vitamin A toxicity. Am. J. Clin. Nutr. 52, 183–202. 
https://doi.org/10.1093/ajcn/52.2.183 
Howley, M.M. et al., 2016. Fluconazole use and birth defects in the National Birth Defects 
Prevention Study. Am. J. Obstet. Gynecol. 214, 657.e1-657.e9. 
https://doi.org/10.1016/j.ajog.2015.11.022 
Klug, S. et al., 1989. All-trans retinoic acid and 13-cis-retinoic acid in the rat whole-embryo 
culture: abnormal development due to the all-trans isomer. Arch. Toxicol. 63, 440–444. 
https://doi.org/10.1007/BF00316445 
Lammer, E.J. et al., 1985. Retinoic Acid Embryopathy. N. Engl. J. Med. 313, 837–841. 
https://doi.org/10.1056/NEJM198510033131401 
Lee, B.E. et al., 1992. Congenital malformations in an infant born to a woman treated with 
fluconazole. Pediatr. Infect. Dis. J. 11, 1062–1064. 
Lee et al., 2017. Perturbation of retinoid homeostasis increases malformation risk in embryos 
exposed to pregestational diabetes. Diabetes 66, 1041-1051. 
 
Lopez-Rangel, E., Van Allen, M.I., 2005. Prenatal exposure to fluconazole: An identifiable 
dysmorphic phenotype. Birt. Defects Res. A. Clin. Mol. Teratol. 73, 919–923. 
https://doi.org/10.1002/bdra.20189 
 13 
Menegola, E. et al., 2000. in vitro teratogenic potential of two antifungal triazoles: triadimefon and 
triadimenol. Vitro Cell. Dev. Biol. - Anim. 36, 88. https://doi.org/10.1290/1071-
2690(2000)036<0088:IVTPOT>2.0.CO;2 
Menegola, E et al., 2001. Antifungal triazoles induce malformations in vitro. Reprod. Toxicol. 15, 
421–427. https://doi.org/10.1016/S0890-6238(01)00143-5 
Menegola, E et al., 2003. Pathogenic pathways in fluconazole-induced branchial arch 
malformations. Birt. Defects Res. A. Clin. Mol. Teratol. 67, 116–124. 
https://doi.org/10.1002/bdra.10022 
Menegola, E. et al., 2004. Relationship between hindbrain segmentation, neural crest cell migration 
and branchial arch abnormalities in rat embryos exposed to fluconazole and retinoic acid in 
vitro. Reprod. Toxicol. 18, 121–130. https://doi.org/10.1016/j.reprotox.2003.09.004 
Menegola, E. et al., 2005. Study on the common teratogenic pathway elicited by the fungicides 
triazole-derivatives. Toxicol. In Vitro 19, 737–748. https://doi.org/10.1016/j.tiv.2005.04.005 
Menegola, E. et al., 2013. Effects of mixtures of azole fungicides in postimplantation rat whole-
embryo cultures. Arch. Toxicol. 87, 1989–1997. https://doi.org/10.1007/s00204-013-1048-y 
Metzler, M., Sandell, L., 2016. Enzymatic Metabolism of Vitamin A in Developing Vertebrate 
Embryos. Nutrients 8, 812. https://doi.org/10.3390/nu8120812 
Moretto, A. et al., 2015. The use of in vitro testing to refine cumulative assessment groups of 
pesticides: The example of teratogenic conazoles. Food Chem. Toxicol. 79, 65–69. 
https://doi.org/10.1016/j.fct.2014.07.006 
Morriss-Kay, G., 1992. Retinoic Acid and Development. Pathobiology 60, 264–270. 
https://doi.org/10.1159/000163733 
Mossey, P.A. et al.., 2009. Cleft lip and palate. The Lancet 374, 1773–1785. 
https://doi.org/10.1016/S0140-6736(09)60695-4 
New, D.A.T., 1978. Whole-embryo culture and the study of mammalian embryos during 
organogenesis. Biol. Rev. 53, 81–122. https://doi.org/10.1111/j.1469-185X.1978.tb00993.x 
 14 
Piersma et al., 2008 tox sci 
Piersma, A.H., Hessel, E.V., Staal, Y.C., 2017. Retinoic acid in developmental toxicology: 
Teratogen, morphogen and biomarker. Reprod. Toxicol. 72, 53–61. 
https://doi.org/10.1016/j.reprotox.2017.05.014 
Punt, A., Peijnenburg. A.A.C.M., Hoogenboom, R.L.A.P., Bouwmeester, H., 2017. Non-animal 
approaches for toxicokinetics in risk evaluations of food chemicals. ALTEX 34, 501-514. 
https://doi.org/10.1473/altex.1702211. 
 
Pursley, T.J. et al., 1996. Fluconazole-Induced Congenital Anomalies in Three Infants. Clin. Infect. 
Dis. 22, 336–340. https://doi.org/10.1093/clinids/22.2.336 
Robinson, J.F. et al., 2012. Triazole induced concentration-related gene signatures in rat whole 
embryo culture. Reprod. Toxicol. 34, 275–283. 
https://doi.org/10.1016/j.reprotox.2012.05.088 
Sanchez, J.M., Moya, G., 1998. Fluconazole teratogenicity. Prenat. Diagn. 18, 862–863. 
https://doi.org/10.1002/(SICI)1097-0223(199808)18:8<862::AID-PD347>3.0.CO;2-F 
Slob, W., 2002. Dose-Response Modeling of Continuous Endpoints. Toxicol. Sci. 66, 298–312. 
https://doi.org/10.1093/toxsci/66.2.298 
Slob, W., Setzer, R.W., 2014. Shape and steepness of toxicological dose–response relationships of 
continuous endpoints. Crit. Rev. Toxicol. 44, 270–297. 
https://doi.org/10.3109/10408444.2013.853726 
Tachibana, M., Noguchi, N., Monro, A., 1987. Toxicology of fluconazole in experimental animals., 
in: Fromtling RA, Editor. Recent Trends in the Discovery, Development, and Evaluation of 
Antifungal Agents. J Proust Science Publishers, Barcelona, Spain, pp. 93–102. 
Tan, Y-M., Worley, R.R., Leonard, J.A., Fisher, J.W., 2018. Challenges associated with applying 
physiologically based pharmacokinetic modeling for public health decision-making. Tox. 
Sci. 162, 341-348. https://doi.org/10.1093/toxsci/kfy010.  
 15 
Tiboni, G.M., 1993. Second branchial arch anomalies induced by fluconazole, a bis-triazole 
antifungal agent, in cultured mouse embryos. Res. Commun. Chem. Pathol. Pharmacol. 79, 
381–384. 
Tiboni, G.M., Marotta, F., Carletti, E., 2009. Fluconazole alters CYP26 gene expression in mouse 
embryos. Reprod. Toxicol. 27, 199–202. https://doi.org/10.1016/j.reprotox.2009.01.001 
Warkany, J., Schraffenberger, E., 1944. Congenital Malformations of the Eyes Induced in Rats by 
Maternal Vitamin A Deficiency. Exp. Biol. Med. 57, 49–52. 
https://doi.org/10.3181/00379727-57-14695P 
Zhang, C., Ball, J., Panzica-Kelly, J., Augustine-Rauch, K., 2016. In Vitro Developmental 
Toxicology Screens: A Report on the Progress of the Methodology and Future Applications. 
Chem. Res. Toxicol. 29, 534–544. https://doi.org/10.1021/acs.chemrestox.5b00458 
  
  
 16 
FIGURE LEGEND 
Fig 1: Evaluation of general and branchial morphology (in the rectangles) 48 h in culture. On the 
right corner: scheme illustrating branchial arch morphology. 
A) normal embryo dorsally convex with a tripartite encephalon with enlarged ventricles (fb, 
forebrain; mb, midbrain; hb, hindbrain); otic (#) and optic (*) vesicles; regular somite disposition 
(s); looped heart (h) three well separated branchial arches (I- II- III); B-E) abnormal branchial arch 
morphology: B) II-III unseparated branchial arches; C) I-II-III branchial arches ventrally fused 
(dorsal radicles visible);D) I-II-III branchial arches totally fused (dorsal radicles undistinguishable); 
E) I-II-III branchial arches forming an unique mass. 
Magnification 20x . 
Fig 2: single dose-response curves of RA. 
Fig 3: single dose-response curves of CYPRO. 
Fig 4: single dose-response curves of FON. 
Fig 5: single dose-response curves of FLUSI. 
Fig 6: single dose-response curves of PCZ. 
Fig 7: evaluation of the relative potency factors (RPFs) of the effects of CYPRO, FON, FLUSI, 
PCZ in respect to RA. From left to right: RA-FLUSI-PCZ-CYPRO-FON.  
 
Table 1. Percentage of embryos with malformations at the branchial arches (BA).  
Grey columns indicate concentration levels at which extra-branchial defects were also observed.        
 
 
 
 
RETINOIC ACID RA 0 m M RA 0.025 m M RA 0.05 m M RA 0.125 m M RA 0.25 m M RA 0.5 m M RA 1 m M
BA abnormalities  0.0 0.0 37.5 73.7 88.2 85.7 100.0
       II-III BA unseparated 0.0 0.0 25.0 5.3 0.0 0.0 0.0
       I-II-III BA vetrally fused 0.0 0.0 12.5 57.9 41.2 7.1 0.0
       I-II-III BA fused without dorsal part visible 0.0 0.0 0.0 5.3 11.8 39.3 0.0
       I-II-III BA fused in a unique mass 0.0 0.0 0.0 5.3 35.3 39.3 100.0
CYPROCONAZOLE CYPRO 0 m M CYPRO 7.8 m M CYPRO 15 m M CYPRO 31 m M CYPRO 46.8 m M CYPRO 62.5 m M CYPRO 125 m M CYPRO 250 m M
BA abnormalities   0.0 20.0 22.2 90.0 100.0 100.0 100.0 100.0
       II-III BA unseparated 0.0 13.3 22.2 70.0 0.0 0.0 0.0 0.0
       I-II-III BA vetrally fused 0.0 6.7 0.0 20.0 22.2 66.7 20.0 0.0
       I-II-III BA fused without dorsal part visible 0.0 0.0 0.0 0.0 66.7 33.3 0.0 0.0
       I-II-III BA fused in a unique mass 0.0 0.0 0.0 0.0 11.1 0.0 80.0 100.0
FLUSILAZOLE FLUSI 0 m M FLUSI 1.56 m M FLUSI 3.125 m M FLUSI 4.8 m M FLUSI 6.25 m M FLUSI 7.7 m M FLUSI 9.375 m M FLUSI 10.1 m M FLUSI 12.5 m M
BA abnormalities   0.0 0.0 36.4 100.0 77.8 100.0 100.0 100.0 100.0
       II-III BA unseparated 0.0 0.0 27.3 40.0 33.3 44.4 40.0 0.0 0.0
       I-II-III BA vetrally fused 0.0 0.0 9.1 20.0 33.3 22.2 40.0 42.9 20.0
       I-II-III BA fused without dorsal part visible 0.0 0.0 0.0 40.0 11.1 33.3 20.0 42.9 80.0
       I-II-III BA fused in a unique mass 0.0 0.0 0.0 0.0 0.0 0.0 0.0 14.3 0.0
TRIADIMEFON FON 0 m M FON 6.25 m M FON 12.5 m M FON 25 m M FON 26.7 m M FON 42.85 m M FON 50 m M FON 56 m M FON 125 m M
BA abnormalities   0.0 0.0 18.2 37.5 90.0 100.0 100.0 100.0 100.0
       II-III BA unseparated 0.0 0.0 9.1 37.5 70.0 50.0 50.0 0.0 0.0
       I-II-III BA vetrally fused 0.0 0.0 9.1 0.0 20.0 50.0 16.7 37.5 0.0
       I-II-III BA fused without dorsal part visible 0.0 0.0 0.0 0.0 0.0 0.0 33.3 50.0 0.0
       I-II-III BA fused in a unique mass 0.0 0.0 0.0 0.0 0.0 0.0 0.0 12.5 100.0
PROCHLORAZ PCZ 0 m M PCZ 6.25 m M PCZ 12.5 m M PCZ 25 m M PCZ 50 m M
BA abnormalities   0.0 11.1 46.7 77.8 77.8
       II-III BA unseparated 0.0 11.1 46.7 44.4 33.3
       I-II-III BA vetrally fused 0.0 0.0 0.0 33.3 33.3
       I-II-III BA fused without dorsal part visible 0.0 0.0 0.0 0.0 11.1
       I-II-III BA fused in a unique mass 0.0 0.0 0.0 0.0 0.0
 
Table
Table 2. Parameters obtained by PROAST analysis, fitting separate dataset for each 
compound and combined dataset for all.  
BMD= benchmark dose; BMR= benchmark response;  
 
 
  
BMD for BMR 50% 
(µM) 
 
log-likelihood   
RA 0.16 -57.69 
CYPRO 19.16 -16.65 
FON 22.15 -16.67 
FLUSI 3.7 -17.18 
PCZ 18.21 -24.12 
   
COMBINED 
(RA as index) 
 
0.1238 
 
-129.13 
 
 
Table
 Table 3. Relative potency factors obtained by PROAST analysis, fitting combined dataset. 
RPF= relative potency factor. 
 
 
 
 
 
 
 
  
RA 
 
 
CYPRO 
 
FON 
 
FLUSI 
 
PCZ 
 
RPF (CI) 
 
1 
 
 
0.0077 
(0.00543-
0.011) 
 
 
0.0069 
(0.005- 
0.0095) 
 
0.043 
(0.0315-
0.0591) 
 
0.0079 
(0.0055-
0.0113) 
Table
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